The Single Biggest Cannabis Catalyst in Years Is Rapidly Approaching: 2 Marijuana Stocks to Buy Now

Cannabis rescheduling to Schedule III is a meaningful positive for the industry because it would allow medical marijuana companies to take standard tax deductions, with a possible second-stage shift for adult-use cannabis still pending. Green Thumb reported Q1 revenue of $300.2 million (+7.4% y/y), EPS of $0.07 (+75%), and holds $344.5 million in cash versus $289.9 million in debt, while Tilray posted record Q3 revenue of $206.7 million (+11% y/y), 73% international sales growth, and reaffirmed full-year adjusted EBITDA guidance of $62 million to $72 million. The article is constructive on both names, especially Tilray for U.S. expansion optionality, but notes regulatory and legal uncertainty remains.

Analysis

The market is pricing this as a broad cannabis rerating, but the first-order winners are actually balance-sheet survivors with existing distribution and brand equity. The tax change matters most for operators already near breakeven: every percentage point of gross margin preserved now converts more directly into cash, so names with cleaner debt and positive EBITDA inflect faster than the highly levered assets that have already run. That favors TLRY on optionality and GTBIF on quality, while the weakest operators may still underperform once the initial headline momentum fades.

The second-order effect is a competitive reset in packaging, beverages, and medical distribution rather than a pure dispensary spread game. Tilray’s non-cannabis beverage network is strategically more valuable than it looks because it gives the company an immediate route to shelf space and retail relationships if federal rules loosen further; that is a much lower-cost entry point than building a U.S. footprint from scratch. Green Thumb’s brand portfolio should also help it defend pricing in a market where commodity flower remains under pressure, but the bigger margin expansion comes from mix shift into branded products and away from undifferentiated product.

The main risk is that the market is extrapolating a legal event into an earnings event too quickly. Even if the rescheduling stands, litigation and banking reform are separate gating items, and the cash benefit from tax relief may be delayed by unresolved prior liabilities. That argues for a months-long rather than days-long horizon; if the June hearings disappoint or courts slow implementation, the sector could give back a large portion of the recent move, especially in the names that already priced in the cleanest outcome.

Key Decisions for Investors

• Long TLRY on a 3-6 month horizon; best risk/reward is on a pullback rather than strength, targeting further rerating if U.S. optionality becomes actionable. Use a starter position now and add only if legal process remains constructive.
• Prefer GTBIF over the most levered MSOs as a defensive quality long; the trade is that you pay up for durability, but you avoid the highest balance-sheet risk if the legal timeline slips.
• Pair trade: long TLRY / short a basket of the most extended cannabis names that already rallied hardest on the headline. The relative value thesis is that future upside comes from operational leverage, not just regulatory beta.
• Avoid chasing the recent winners until post-hearing confirmation; implied downside is larger than upside over the next 2-4 weeks if the court challenge or legislative process creates a delay.
• If you want pure event-driven exposure, express it with call spreads in TLRY into the June hearing window to cap premium risk while preserving upside to a positive regulatory surprise.